AddLife AB (publ) (ADDLF) Q3 2026 Earnings Call Transcript

AddLife reported Q3 2026 sales growth of 7%, supported by organic momentum and acquired growth, while acquisition activity increased. Overall margins strengthened to 11.5%, with a strong increase in Labtech and a minor decrease in Medtech, which management described as relatively stable; operating cash flow improved significantly.

Analysis

The useful signal is operating leverage, not the headline growth rate: if the margin improvement persists, EBIT can outpace sales and strengthen funding capacity for bolt-on deals. But acquired growth and organic momentum are bundled together, so the 7% figure does not establish the underlying demand trajectory. Segment divergence matters: Labtech is currently carrying the margin improvement, while Medtech is not; a shift in mix or continued Medtech pressure could unwind group-level gains.

Improved operating cash flow reduces near-term execution risk, but faster acquisition activity raises the medium-term bar for disclosure on purchase prices, integration, and returns. Over 1–3 months, verify organic growth by segment, comparable margins, cash conversion, and acquisition contribution. Over 6–18 months, the key question is whether acquired businesses sustain returns without leverage or goodwill becoming a constraint. The release excerpt is insufficient to assess valuation or balance-sheet capacity.

No direct earnings read-through to ADDT.B or BERG.B: the article mentions Addtech and Bergman & Beving as historical roots, not as businesses affected by these results. Their relevance is limited to investor comparison of decentralized acquisition models, not operational exposure. The positive tone could be over-interpreted if investors treat acquisition-led growth as durable organic acceleration.

Key Decisions for Investors

• Avoid chasing the positive headline alone; treat AddLife as a watch pending the full report’s organic growth, segment margins, net debt, and acquisition contribution.
• If subsequent reporting confirms sustained Labtech margin gains and stronger cash conversion without rising leverage, consider building exposure on a pullback rather than buying the initial reaction.
• Falsify the constructive view if organic growth weakens materially, Medtech margins deteriorate further, or cash conversion fails to track reported operating profit; reassess after the next results or material acquisition disclosure.
• Do not use ADDT.B or BERG.B as direct proxies for AddLife’s result; any relative-value trade would require separate evidence of valuation or investor-flow spillover.